Masimo (MASI) to Release Quarterly Earnings on Thursday

Masimo (NASDAQ:MASI) will likely be posting its Q4 2025 results after the market closes on Thursday, February 26th. Analysts expect Masimo to post earnings of $1.41 per share and revenue of $407.9730 million for the quarter. Investors may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Thursday, February 26, 2026 at 4:30 PM ET.

Masimo Stock Performance

NASDAQ MASI opened at $175.61 on Thursday. Masimo has a twelve month low of $125.94 and a twelve month high of $194.88. The company has a quick ratio of 1.92, a current ratio of 2.84 and a debt-to-equity ratio of 0.69. The stock has a market cap of $9.43 billion, a P/E ratio of -16.66, a PEG ratio of 1.77 and a beta of 1.26. The company’s 50-day simple moving average is $137.72 and its 200 day simple moving average is $142.84.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on MASI shares. Piper Sandler lowered Masimo from an “overweight” rating to a “hold” rating and set a $180.00 price objective on the stock. in a research note on Tuesday. BTIG Research cut Masimo from a “buy” rating to a “neutral” rating in a research report on Wednesday. Stifel Nicolaus set a $180.00 price objective on Masimo in a research note on Tuesday. Zacks Research cut shares of Masimo from a “strong-buy” rating to a “hold” rating in a research report on Friday, October 24th. Finally, Needham & Company LLC restated a “hold” rating on shares of Masimo in a research report on Monday, December 1st. One equities research analyst has rated the stock with a Buy rating, six have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $181.17.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in MASI. Mercer Global Advisors Inc. ADV bought a new position in shares of Masimo in the fourth quarter worth about $1,413,000. Naya Capital Management UK Ltd. acquired a new stake in shares of Masimo in the fourth quarter valued at approximately $202,984,000. XTX Topco Ltd bought a new position in Masimo in the 4th quarter worth approximately $1,658,000. nVerses Capital LLC acquired a new position in Masimo during the 4th quarter worth $269,000. Finally, Voloridge Investment Management LLC lifted its holdings in Masimo by 1,281.7% during the 4th quarter. Voloridge Investment Management LLC now owns 39,557 shares of the medical equipment provider’s stock worth $5,145,000 after buying an additional 36,694 shares in the last quarter. Institutional investors and hedge funds own 85.96% of the company’s stock.

Key Masimo News

Here are the key news stories impacting Masimo this week:

• Positive Sentiment: Danaher agreed to acquire Masimo for $180 per share in cash (~$9.9B), giving investors a clear near‑term valuation anchor and a sizeable premium to pre‑deal levels. Danaher To Acquire Masimo Corporation
• Positive Sentiment: Market reaction: MASI surged on the deal (investors captured roughly a ~34% jump when the news broke), and the stock is trading at elevated volume as merger‑arbitrage activity prices in deal close probability and timing. Masimo shares jump 34% after Danaher agrees to buy the company
• Positive Sentiment: Analyst take on the deal: coverage notes Danaher’s purchase presents solid long‑term financial upside and conservative growth assumptions under new ownership, supporting the strategic rationale for the acquisition. Danaher’s Masimo Acquisition: Solid Financials, Conservative Growth Projections
• Neutral Sentiment: Wells Fargo reaffirmed an “equal weight” rating but trimmed its price target to $180 (from $190), effectively aligning its target with the cash offer and signaling limited upside beyond the deal price. Wells Fargo rating / Benzinga
• Neutral Sentiment: Founder/management commentary: founder Joe Kiani and company coverage pieces are framing the sale and future under Danaher; such commentary helps set expectations for integration and standalone operations post‑close. Masimo Founder Joe Kiani On The Healthtech Company’s $10 Billion Acquisition
• Negative Sentiment: Multiple law firms have launched investigations and shareholder groups are probing whether Masimo’s board obtained a fair price, creating potential legal/transactional risk that could delay or alter the deal terms. Shareholder Alert: M&A Class Action Firm Investigating Masimo

About Masimo

Masimo (NASDAQ: MASI) is a global medical technology company specializing in noninvasive monitoring solutions. The company’s flagship technology, Masimo SET® (Signal Extraction Technology), enhances the accuracy of pulse oximetry in challenging clinical conditions. Beyond pulse oximetry, Masimo’s portfolio extends to brain function monitoring, regional oximetry, and acoustic respiration rate monitoring, serving critical, acute, and ambulatory care settings.

In addition to its core monitoring technologies, Masimo offers a range of patient cables, sensors, and connectivity platforms designed to integrate with hospital information systems and remote monitoring applications.